UCB Investment to Push Alpha-Synuclein Targeting Therapy into Clinical Testing

Research-1Pharmaceutical company Neuropore Therapies will team up with Belgian drugmaker UCB in a $480 million deal to study early-stage treatments for Parkinson’s disease.

An MJFF grant recipient, Neuropore was selected for the Synuclein Therapeutic Acceleration Program in 2010 and 2013 and for the 1H 2014 Partnering Program for the preclinical study of its drug NPT200-11 on preventing toxicity of the protein alpha-synuclein, which misfolds in all cases of Parkinson’s disease.

Following positive preclinical results, Neuropore’s NPT200-11 has attracted UCB’s attention, resulting in the $480 million in follow-on funding, pushing the drug further through the pipeline. NPT200-11 is expected to move into its first clinical trial later this year.

Find out more on other research relating to alpha-synuclein in Parkinson’s disease

Source:   The Michael J. Fox Foundation for Parkinson’s Research